CRSP Jul 2024 77.500 call
| Previous Close | 0.2600 |
| Open | 0.2700 |
| Bid | 0.0000 |
| Ask | 1.1500 |
| Strike | 77.50 |
| Expire Date | 2024-07-19 |
| Day's Range | 0.2600 - 0.2700 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 53 |
ZacksCRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
GlobeNewswireCRISPR Therapeutics to Participate in Upcoming Investor Conferences
ZUG, Switzerland and BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in June. Jefferies Healthcare ConferenceDate: Wednesday, June 5, 2024Time: 10:00 a.m. ET Goldman Sach’s 45th Annual Global Healthcare ConferenceDate: Tuesday, June 11, 20
- GlobeNewswire
CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments
-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer- ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Naimish Patel, M.D., as Chief Medical Officer, effective May 28, 2024. Dr. Patel is an experienced drug developer who has worked across a wid
